Nahua Bio Completes Tens of Millions of RMB Series A+ Financing Led by Shenzhen Capital Group and Galaxy Capital

VCBeat (WeChat: vcbeat) has learned that Nahua Biotech (Changzhou) Co., Ltd. (“Nahua Biotech”) recently completed an A+ financing round amounting to tens of millions of RMB. This round was jointly invested by SCGC and Galaxy Capital. The funds will be primarily used for the development, promotion, and sales of the company’s existing products in sports medicine, dental consumables, and minimally invasive surgical consumables.

Previously, Nahua Biology had completed angel, Pre-A, and Series A financing rounds totaling over RMB 100 million. Investors included Wuyuefeng Capital and senior entrepreneurs in the domestic orthopedic and surgical medical device sectors.

Nahua Biologics, established in 2013, possesses two globally unique and leading platform technologies: “Nanofiber-Reinforced Composite Materials” and “Low-Temperature Plasma.” The “Nanofiber-Reinforced Composite Materials” technology empowers sports medicine and dental products, while “Low-Temperature Plasma” is applied to develop innovative products in dentistry, wound care, and other fields, creating new market opportunities. The research and development of these two core platform technologies began over a decade ago and has successively received multiple grants from the U.S. federal government’s National Institutes of Health (NIH) and National Science Foundation (NSF), totaling millions of U.S. dollars.

Dr. Li Hao, the founder, and the core team have established efficient R&D and operational teams in both China and the United States, with R&D centers and production bases set up in Missouri (USA), Changzhou, and Ningbo (China). The company primarily focuses on high-growth sectors such as minimally invasive surgery (minimally invasive general surgery and sports medicine) and medical aesthetics (dentistry, dermatology/wound care), with product performance ranking among the international leaders. The company holds eight FDA 510(k)-cleared products, has obtained its first Class II medical device registration certificate in China, and has multiple additional products undergoing regulatory review. Its products are already being sold in North America, Latin America, and the Middle East, with sales revenue experiencing steady and rapid growth, while market expansion in China is also underway. Following this round of financing, the company will further accelerate the commercialization of its existing product portfolio and continue to deepen its strategic layout in fields such as sports medicine and dentistry.

Yi Hongxiang, Partner of SCGC Red Soil Medical Fund“Sports medicine and dental consumables represent high-potential sectors with significant room for increased market penetration in China. Nahua’s products are technologically competitive with those of international giants, a rarity among start-ups. We believe that, under the leadership of Dr. Li Hao, Nahua Biotech will rapidly achieve major breakthroughs in new medical materials and products.”

Lu Jian, Managing Director of Star River CapitalHe stated, “The company boasts a first-class R&D team composed of top-tier talent from various fields, including American professors, PhDs, physicians, and engineers. They have developed multiple platform technologies and created products with technical specifications that are internationally leading. Nanhua’s R&D and production bases spanning China and the United States enable the company to strategically develop and manufacture medical device products urgently needed in the domestic market, while also efficiently providing competitive medical device products to the international market. Since its establishment, the company has gained recognition from both the investment and industrial sectors. Shenzhen Century Star River Capital Management Co., Ltd. is highly optimistic about the company’s future growth.”